Benjamin J. Hickey's most recent trade in Mural Oncology plc was a trade of 8,637 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mural Oncology plc | Benjamin J. Hickey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 8,637 | 8,637 | - | - | Stock Option (right to buy) | |
| Bristol-Myers Squibb | Benjamin J. Hickey | President, RayzeBio Org. | Sale of securities on an exchange or to another person at price $ 38.16 per share. | 09 May 2025 | 97 | 0 (0%) | 0% | 38.2 | 3,702 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Benjamin J. Hickey | President, RayzeBio Org. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 20,084 | 20,084 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Benjamin J. Hickey | President, RayzeBio Org. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 13,389 | 13,389 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Benjamin J. Hickey | President, RayzeBio Org. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,286 | 6,572 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Benjamin J. Hickey | President, RayzeBio Org. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,286 | 10,419 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Benjamin J. Hickey | President, RayzeBio Org. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.62 per share. | 01 Mar 2025 | 1,630 | 8,789 (0%) | 0% | 59.6 | 97,181 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Benjamin J. Hickey | President, RayzeBio Org. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 10,078 | 20,158 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Benjamin J. Hickey | President, RayzeBio Org. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 10,078 | 10,858 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Benjamin J. Hickey | President, RayzeBio Org. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.95 per share. | 01 Feb 2025 | 3,725 | 7,133 (0%) | 0% | 59.0 | 219,589 | Common Stock, $0.10 par value |
| Mural Oncology plc | Benjamin J. Hickey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 8,462 | 8,462 | - | - | Stock Option (right to buy) | |
| Mural Oncology plc | Benjamin J. Hickey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 8,462 | 8,462 | - | - | Stock Option (right to buy) | |
| Mural Oncology plc | Benjamin J. Hickey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 15,021 | 15,021 | - | - | Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Hickey Benjamin J. | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 56.67 per share. | 13 Dec 2023 | 2,220 | 103,694 (0%) | 0% | 56.7 | 125,807 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 37.00 per share. | 09 Aug 2023 | 22,297 | 105,914 (0%) | 0% | 37 | 824,989 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 45,456 | 45,456 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 36,394 | 83,617 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 42.38 per share. | 17 Jan 2023 | 947 | 47,842 (0%) | 0% | 42.4 | 40,132 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 42.38 per share. | 17 Jan 2023 | 619 | 47,223 (0%) | 0% | 42.4 | 26,234 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 45.37 per share. | 09 Jan 2023 | 2,088 | 48,789 (0%) | 0% | 45.4 | 94,733 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 19,149 | 54,125 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 40.41 per share. | 19 Dec 2022 | 3,248 | 50,877 (0%) | 0% | 40.4 | 131,266 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 17,821 | 17,821 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 10,755 | 35,603 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 120.48 per share. | 14 Jan 2022 | 627 | 34,976 (0%) | 0% | 120.5 | 75,543 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2021 | 2,369 | 30,116 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 114.33 per share. | 19 Mar 2021 | 2,369 | 29,181 (0%) | 0% | 114.3 | 270,848 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 176.42 per share. | 19 Mar 2021 | 1,350 | 27,243 (0%) | 0% | 176.4 | 238,171 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 175.54 per share. | 19 Mar 2021 | 588 | 28,593 (0%) | 0% | 175.5 | 103,216 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 177.71 per share. | 19 Mar 2021 | 431 | 26,812 (0%) | 0% | 177.7 | 76,591 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 10,979 | 10,979 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 7,023 | 26,812 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 216.33 per share. | 07 Jan 2021 | 2,069 | 19,789 (0%) | 0% | 216.3 | 447,587 | Common Stock |
| Mirati Therapeutics Inc | Benjamin J. Hickey | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 215.33 per share. | 07 Jan 2021 | 9 | 21,858 (0%) | 0% | 215.3 | 1,938 | Common Stock |